Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 18/20 | 0.53 |
| ▸ | PCTP | Q9UKL6 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | STARD7 | Q9NQZ5 | 1/20 | 0.42 |
| ▸ | STARD10 | Q9Y365 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406945 | 0.91 | GHSR (0.53) | GHSRPCTPSTARD7STARD10 | |
| SCHEMBL19377401 | 0.89 | GHSR (0.70) | GHSRPCTPADRB3 | |
| SCHEMBL19377260 | 0.88 | PCTP (0.46) | GHSRPCTPSTARD7STARD10 | |
| SCHEMBL19377387 | 0.80 | GHSR (0.45) | GHSRPCTPSTARD7STARD10 | |
| SCHEMBL11232803 | 0.73 | PCTP (0.59) | PCTPSTARD10 | |
| SCHEMBL19377037 | 0.73 | GHSR (0.58) | GHSRADRB3 | |
| SCHEMBL19377337 | 0.72 | GHSR (0.53) | GHSRADRB3 | |
| SCHEMBL19377338 | 0.72 | GHSR (0.53) | GHSRADRB3 | |
| SCHEMBL24800034 | 0.71 | GHSR (0.50) | GHSR | |
| SCHEMBL19377110 | 0.71 | DRD2 (0.54) | GHSRPCTPSTARD7STARD10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | GHSR 2/4885PCTP 2942/4885ADRB3 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.